Carisma Therapeutics Inc
NASDAQ:CARM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
N
|
Nanjing Sinolife United Co Ltd
HKEX:3332
|
CN |
|
Hubei Guangji Pharmaceutical Co Ltd
SZSE:000952
|
CN |
Carisma Therapeutics Inc
Interest Expense
Carisma Therapeutics Inc
Interest Expense Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Interest Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Carisma Therapeutics Inc
NASDAQ:CARM
|
Interest Expense
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Interest Expense
$2.9B
|
CAGR 3-Years
9%
|
CAGR 5-Years
3%
|
CAGR 10-Years
15%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Interest Expense
$1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
1%
|
CAGR 10-Years
4%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Interest Expense
$2.8B
|
CAGR 3-Years
25%
|
CAGR 5-Years
17%
|
CAGR 10-Years
10%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Interest Expense
$13.3m
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
-17%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Interest Expense
$43.8m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
12%
|
|
Carisma Therapeutics Inc
Glance View
Carisma Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of immunotherapies. The company is headquartered in Cambridge, Massachusetts and currently employs 17 full-time employees. The company went IPO on 2014-02-06. The firm is focused on discovering and developing immunotherapies for patients with cancer and other serious disorders. Its platform is focused on engineered macrophages, cells that plays a role in both the innate and adaptive immune response. Its pipeline includes multiple chimeric antigen receptor (CAR) macrophages designed to target solid tumors by engineering a patient’s own immune cells. Its technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and cellular therapy for the treatment of human disease. The firm's pipeline includes CT-0508, CT-0525, CT-1119 and CT-0729. Its CT-0508 and CT-0525 is an ex vivo gene-modified autologous CAR-Macrophage cellular therapy to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2) metastasis. Its CT-1119 is a ex vivo gene-modified autologous CAR-Macrophage cellular therapy.
